|
gptkbp:instanceOf
|
gptkb:drug
antiemetic
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:A04AD12
|
|
gptkbp:brand
|
gptkb:Emend
|
|
gptkbp:CASNumber
|
gptkb:170729-80-3
|
|
gptkbp:category
|
antiemetics
neurokinin receptor antagonists
|
|
gptkbp:chemicalClass
|
morpholine derivative
|
|
gptkbp:contraindication
|
concurrent use with pimozide
hypersensitivity to aprepitant
|
|
gptkbp:discoveredBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
9-13 hours
|
|
gptkbp:form
|
capsule
oral suspension
|
|
gptkbp:hasMolecularFormula
|
C23H21F7N4O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aprepitant
|
|
gptkbp:inducedBy
|
gptkb:CYP2C9
|
|
gptkbp:inhibitedBy
|
gptkb:CYP3A4
|
|
gptkbp:interactsWith
|
gptkb:rifampin
gptkb:warfarin
gptkb:dexamethasone
gptkb:ketoconazole
gptkb:midazolam
oral contraceptives
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
neurokinin-1 receptor antagonist
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
534.43 g/mol
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:PubChem_CID
|
6918365
DB00673
|
|
gptkbp:relatedTo
|
gptkb:fosaprepitant
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
anorexia
constipation
fatigue
headache
hiccups
|
|
gptkbp:UNII
|
J3M7L9675F
|
|
gptkbp:usedFor
|
prevention of postoperative nausea and vomiting
prevention of chemotherapy-induced nausea and vomiting
|
|
gptkbp:bfsParent
|
gptkb:Antiemetics
|
|
gptkbp:bfsLayer
|
6
|